Probiotic oral colonization tablet
By using bioadhesive coating layer and modified xanthan gum in probiotic oral colonization tablets, the problem of low bioavailability of existing probiotic preparations is solved, and effective colonization of probiotics in periodontal pockets is achieved. and long-term retention improves the therapeutic effect of periodontitis and tooth caries.
Patent Information
- Application Number
- CN202411290113.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-14
AI Technical Summary
The existing oral probiotic preparations have low bioavailability and are unable to effectively engraft on the periodontal pocket area, resulting in poor efficacy in treating periodontitis.
A probiotic oral colonization sheet was designed, using a bioadhesive coating layer to coat the sheet core, and using casein phosphopeptide-amorphous calcium phosphate and L-cysteine to modify xanthan gum and other materials to enhance the probiotics. Adhesion and stability ensure effective colonization in oral environment.
It significantly improves the bioavailability and retention time of probiotics in the oral environment, enhances the therapeutic effect on periodontitis and caries, and avoids the problem of probiotics being lost due to saliva flow.
Smart Images

Figure CN119074675A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a probiotic oral colonization tablet. Background Art
[0002] The main cause of periodontal disease is bacterial infection. The oral cavity is a habitat for multiple bacteria. Pathogenic bacteria attach to the tooth surface and gingival sulcus in the form of plaque, and there is also non-attached plaque with stronger pathogenicity in the periodontal pocket. Therefore, anatomical variations, bad habits, poor oral restorations, combined lesions, etc. can all help the local retention and aggregation of pathogenic bacteria. If oral hygiene measures are not paid attention to or strengthened, the progression and manifestation of periodontal lesions will be aggravated, regardless of whether there are systemic diseases or a decline in overall health, and thus affect normal chewing and occlusion. At the same time, the lack of awareness of oral health and medical treatment among the population is also an important reason.
[0003] In the early stages of periodontitis, prevention and cleaning are the main focus. General treatments for periodontitis include: controlling oral plaque and maintaining oral hygiene; removing tartar and washing teeth regularly; removing factors that cause plaque retention, such as treating food impaction and filling caries. Drug treatment for periodontitis: Drug treatment alone is not the main means of treating periodontal disease. For patients who do not respond to mechanical treatment, auxiliary medication may be considered. The use of antibiotics to treat periodontitis is effective in the short term, but long-term use can lead to drug resistance, decreased efficacy, and recurrence of the disease. Surgical treatment of periodontitis: When periodontitis is severe, surgical treatment can be performed, mainly flap surgery, bone grafting, guided tissue regeneration, and dental implants.
[0004] In view of the shortcomings of the above-mentioned treatment methods, oral probiotic preparations can be used to prevent periodontitis and treat chronic periodontitis and as auxiliary medications for surgical treatment of periodontitis.
[0005] Lactobacillus rhamnosus (LGG) is a probiotic that has been widely and safely used in gastrointestinal clinical applications. Existing studies have shown that Lactobacillus rhamnosus can not only act on intestinal flora, but also play an important regulatory role in the microbial environment in the oral cavity. It can regulate the balance of oral flora by inhibiting harmful bacteria to treat periodontal diseases, such as periodontitis caused by Porphyromonas gingivalis and dental caries caused by Streptococcus mutans. At present, there are few types of oral probiotic preparations on the market, and products that use or add oral probiotics are basically health products; the dosage forms are mainly concentrated in lozenges, powders, mouthwashes, and chewing gums, and most of them are foreign products. Ordinary probiotic oral lozenges have low bioavailability of live bacteria, and are mostly used in the treatment of halitosis and dental caries. There are few products for the prevention and treatment of periodontitis, and they cannot be deeply implanted in the periodontal pocket to effectively inhibit Porphyromonas gingivalis and thus treat periodontitis.
[0006] Therefore, the present application designs an oral colonization tablet based on the mucosal adhesion mechanism to promote the large-scale colonization of probiotics in the oral cavity and thus regulate the oral flora, and then treat corresponding diseases such as periodontitis and caries. Summary of the invention
[0007] The object of the present invention is to provide a probiotic oral colonization tablet, comprising a tablet core and a bioadhesive coating layer, wherein the bioadhesive coating layer is coated on the outside of the tablet core;
[0008] The probiotic oral implantation tablet is prepared by the following steps:
[0009] Step 1, mixing a portion of the prescribed amount of probiotic freeze-dried powder, biomineralization material, filler, disintegrant and lubricant, and directly tableting to obtain tablet cores;
[0010] Step 2, mix the remaining amount of the probiotic lyophilized powder, the biological mucosal adhesive material and the adhesive, take part of the mixture and evenly fill it at the bottom of the tablet press die, place the tablet core at the center, then fill it with the remaining amount of the mixture to wrap it, and directly compress it again to obtain the final tablet;
[0011] The biomineralization material is casein phosphopeptide-amorphous calcium phosphate, and the biomucosal adhesion material is xanthan gum and guar gum modified by L-cysteine.
[0012] Furthermore, the probiotic freeze-dried powder is Lactobacillus rhamnosus freeze-dried powder, the filler is selected from microcrystalline cellulose and lactose, the disintegrant is cross-linked polyvinyl pyrrolidone, the lubricant is selected from magnesium stearate, sodium stearate and talc, and the binder is sodium carboxymethyl cellulose.
[0013] Further, the probiotic oral implantation tablet is made of the following raw materials in weight percentage: 1% to 5% of Lactobacillus rhamnosus freeze-dried powder, 1% to 5% of casein phosphopeptide-amorphous calcium phosphate, 5% to 10% of microcrystalline cellulose, 20% to 25% of lactose, 0.5% to 1% of cross-linked polyvinyl pyrrolidone, 0.5% to 2% of magnesium stearate, 5% to 15% of L-cysteine xanthan gum, 2% to 5% of guar gum, and 10% to 20% of sodium carboxymethyl cellulose, and the sum of the weight percentages of all raw materials is 100%. Preferably, the weight ratio of L-cysteine xanthan gum, guar gum and sodium carboxymethyl cellulose is 5:2:8 or 8:5:8, more preferably 5:2:8.
[0014] Furthermore, the preparation method of the L-cysteine-modified xanthan gum is as follows: dissolving xanthan gum in water, adjusting the pH to 5.5, adding EDC and NHS to the solution, adjusting the pH to 7.0, adding L-cysteine to the mixed solution under light-proof conditions, stirring for reaction, dialyzing with demineralized water after the reaction is completed, and freeze-drying after the dialysis is completed to obtain L-cysteine-modified xanthan gum.
[0015] The usage ratio of xanthan gum, EDC and NHS is as follows: 1.5 g of xanthan gum is dissolved in 200 mL of water, and 0.28755 g of EDC (dissolved in 1 mL of water) and 0.17264 g of NHS (dissolved in 4 mL of water) are added thereto; the usage ratio of xanthan gum and L-cysteine is as follows: 1.5 g of xanthan gum is dissolved in 200 mL of water, and then 1.45 g of L-cysteine (dissolved in 25-35 mL of water) is added to react.
[0016] In the present invention, the casein phosphopeptide-amorphous calcium phosphate can be synthesized by the method described in the specification of the present invention, or can be prepared by using a commercially available product, which has no effect on the effect of the implantation sheet of the present invention.
[0017] In view of the fact that most of the existing oral probiotic preparations are ordinary lozenges, which have the problems of low bioavailability, poor probiotic retention effect, and multiple medication times, the present invention designs and prepares an oral adhesive colonization tablet that can significantly enhance the adhesion of tablets in the local oral environment, significantly enhance the bioavailability of probiotics in the oral environment, thereby improving the effective colonization of probiotics. Compared with other common probiotic preparations, it can achieve a more stable release and a longer retention time in vitro, thereby improving the local oral environment bioavailability of the drug, and its preparation process is simple and feasible.
[0018] The invention enhances the bioadhesion of the biomacromolecule material xanthan gum by modifying it with L-cysteine, and improves the solubility of the tablet, so that it can be more fully dissolved within the effective time to meet the needs of the actual oral environment, but the stability of the modified xanthan gum is poor, so guar gum is introduced into the prescription to improve the stability of the modified xanthan gum and promote the stability of the tablet, and the gel consistency can also be further adjusted. At the same time, a biomineralization material used in oral care products, casein phosphopeptide-amorphous calcium phosphate, is added to the tablet. This biomineralization material has the effect of coordinating probiotics to prevent and treat dental caries, and will not affect the biological activity of probiotics, so that the product plays a certain role in local prevention of dental caries while preventing and treating periodontitis.
[0019] The probiotic oral implantation tablet of the present invention adopts a bioadhesive material on the outer layer of the tablet, so that the outer layer of the tablet can quickly adhere to the oral mucosa after being hydrated for a short time, and then gradually release the probiotics in the tablet near the oral lesion site, so as to avoid the large-scale loss of probiotics in the oral cavity due to the flow of saliva like oral lozenges. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The standard curves are L-cysteine and L-leucine.
[0021] Figure 2 This is a scanning electron micrograph of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP).
[0022] Figure 3 This is the swelling picture of modified xanthan gum tablets.
[0023] Figure 4 Swelling curves of tablets made with different mucoadhesive materials.
[0024] Figure 5 The dissolution curves of tablets with drug loading ratios of core to mucosal outer layer of 1:0, 3:1, 2:1, and 1:1, respectively.
[0025] Figure 6 The in vitro dissolution curves of tablets with a core to mucosal outer layer drug loading ratio of 2:1 and 1:1 respectively.
[0026] Figure 7 This is an electron microscope photograph of a tablet with an internal and external drug loading ratio of 1:1 after swelling and solidification.
[0027] Figure 8 These are surface and cross-sectional photographs of the oral implant sheet of the present invention. DETAILED DESCRIPTION
[0028] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.
[0029] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0030] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0031] Example 1
[0032] 1. Preparation of L-cysteine modified xanthan gum
[0033] Step 1: Dissolve 1.5 g xanthan gum in 200 mL pure water and adjust the pH to 5.5;
[0034] Step 2: Add EDC (0.28755 g dissolved in 1 mL pure water) and NHS (0.17264 g dissolved in 4 mL pure water) to the solution to activate the carboxyl group. After stirring for 20 minutes, adjust the pH to 7.0;
[0035] Step 3: Dissolve 1.45 g of L-cysteine in 25-35 mL of pure water and slowly add it to the reactants (be careful to avoid light);
[0036] Step 4: Stir the reaction at room temperature for 6 hours, then collect the sample for dialysis;
[0037] Step 5: dialyze 10 times with 5L of demineralized water (10000-12000Da); after the dialysis is completed, take out the reaction product and put it into a -80°C refrigerator for pre-freezing and wait for freeze-drying.
[0038] 2. Determination of the amount of cysteine modified in L-cysteine-modified xanthan gum
[0039] First, the standard curves for thiol quantification were established by Ellman thiol quantification experiment and OPA free amino group detection experiment. 2 =0.9981) and the standard curve for amino group quantification is Y=0.2971*X-0.05725(R 2 =0.9998). Figure 1 shown.
[0040] The sulfhydryl content was then quantitatively determined as follows:
[0041] (1) Prepare sample solution: weigh 10 mg of modified xanthan gum and dissolve it in Ellman buffer and make up to 5 mL;
[0042] (2) Prepare blank control solution: weigh 10 mg of xanthan gum and dissolve it in buffer and make up to 5 mL;
[0043] (3) Take two test tubes, add 50 μL of Ellman's reagent and 2.5 mL of sodium phosphate buffer solution to each test tube, mix well, add 50 μL of the sample to be tested to each test tube, mix well, and leave at room temperature for 15 minutes. Use xanthan gum solution as a blank and measure the sample absorbance at 412 nm to find that it is 0.31A;
[0044] (4) By substituting the absorbance into the calibration curve Y=0.2357*X-0.04657, the thiol concentration was obtained to be 151.28 μmol / g.
[0045] Finally, the free amino group content in the system is determined as follows:
[0046] (1) Prepare sample solution: weigh 50 mg of modified xanthan gum and dissolve it in 15 mL of water;
[0047] (2) Prepare blank control solution: weigh 50 mg of xanthan gum and dissolve it in 15 mL of water;
[0048] (3) Take two test tubes, add 40 μL of the sample to be tested and 4.8 mL of OPA / NAC reagent to each test tube, mix well, and leave at room temperature for 15 minutes. Use xanthan gum solution as a blank and measure the absorbance of the sample to be tested at 340 nm to find that it is 0.097A;
[0049] (4) By substituting the absorbance into the standard curve Y=0.2971*X-0.05725, the concentration of free amino groups, i.e., cysteine that has not been dialyzed away, was obtained to be 51.92 μmol / g.
[0050] Finally, the calculation showed that the amount of thiol modification on the synthesized L-cysteine-modified xanthan gum was 99.36 μmol / g.
[0051] Example 2
[0052] Synthesis and Identification of Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)
[0053] Casein phosphopeptide-amorphous calcium phosphate is a biomineralized material, which is currently used in many new oral care products. Many famous toothpaste brands (such as Japan Lion) have introduced this material to prevent and relieve tooth decay. The reaction principle is mainly to make the two ends of the casein phosphopeptide gather phosphate and calcium ions respectively through the structure of the casein phosphopeptide, so that the calcium phosphate becomes an amorphous state, and the casein phosphopeptide-amorphous calcium phosphate is obtained. The specific synthesis method is as follows:
[0054] First, add 10 mL of deionized water to a 50 mL beaker, weigh 100 mg of anhydrous calcium chloride and place it in the beaker. After stirring with a glass rod until it is completely dissolved, add 300 mg of CPP and stir gently in a 25°C water bath for 1 h.
[0055] Add 10 mL of deionized water to another 50 mL beaker, weigh 100 mg of Na3PO4 and place it in the beaker, stir with a glass rod to completely dissolve. Then quickly pour the Na3PO4 solution into the CaCl2 solution prepared above, continue to stir gently in a water bath for one hour, transfer to a 50 mL centrifuge tube, and centrifuge at 6000 rpm for 10 minutes. After pouring the supernatant, gently wash the surface of the precipitate with a small amount of deionized water. Disperse the precipitate with 10 mL of deionized water to obtain a CPP-ACP dispersion. For long-term storage, freeze-dry the solution.
[0056] Then, the casein phosphopeptide and the synthetic product casein phosphopeptide-amorphous calcium phosphate were scanned using a Japanese Hitachi SU8010 scanning electron microscope, and the measurement results are as follows: Figure 2As shown. Scanning electron microscopy photos show that the casein phosphopeptide-amorphous calcium phosphate has a significant structural change compared to the reactant, and the casein phosphopeptide has obvious aggregation under the action of calcium phosphate, indicating the successful synthesis of casein phosphopeptide-amorphous calcium phosphate.
[0057] Example 3
[0058] For the dosage ratio of xanthan gum, guar gum and sodium carboxymethyl cellulose, the main substances in the mucosal adhesive outer layer, this embodiment screens the prescription by designing a minimum peeling force test, and evaluates the strength of the bioadhesion of different prescriptions by comparing the minimum separation force that separates the tablet from the mucosal tissue, and then screens out the prescription with the best content ratio. The specific experimental plan is as follows: First, a peristaltic pump is used to set a flow rate of 0.5mL / min to simulate the normal flow rate of saliva in the oral environment. After the artificial saliva flows through the mucosal tissue, each prescription tablet is placed on the mucosal tissue. After standing for 30s, the tablet is peeled off from the tissue by a tensile meter, and the pulling force (g) that causes the tablet to peel off is recorded. Each group of tests is conducted in parallel twice.
[0059] The prescription of the tablets of the present embodiment is as follows:
[0060]
[0061] The experimental results are as follows:
[0062]
[0063] By comprehensively comparing the minimum peeling force required for tablets with different ratios (xanthan gum: guar gum: CMC), it can be seen that tablets with ratios of 8:5:8 and 5:2:8 have relatively the best biomucosa adhesion properties.
[0064] By observing the appearance and other properties of the tablets, it was found that the tablets with a ratio of 5:2:8 had a smoother and neater appearance, so the ratio of 5:2:8 was selected as the outer layer formulation of the tablets. Since polymer materials can interact with each other and play a physical combination role, the gel strength of a single polymer material is enhanced, and the improvement in gel strength can also be reflected in the subsequent swelling test results.
[0065] Example 4
[0066] Proper swelling behavior of the oral adhesive system is necessary for uniform and effective adhesion. The swelling of the tablet increases its weight and volume due to the absorbed liquid. The tablets to be tested are weighed and fixed on a 2×2 cm glass slide to measure the swelling index. The glass slide with the tablet fixed is immersed in 10 ml of artificial saliva (pH 6.8). The study was carried out at a constant temperature of 37±0.5℃. At regular intervals, the tablets were removed from the culture dish, dried with filter paper to remove excess surface water, and then weighed again.
[0067] The formula is as follows: Swelling index (%) = (W2-W1) / W1 x 100%, where W1 is the initial weight of the tablet and W2 is the final weight of the swollen tablet. Each experiment was repeated three times.
[0068] The prescription of the tablets of the present embodiment is as follows:
[0069]
[0070] like Figure 3 As shown in the figure, during the prescription screening process, the modified xanthan gum tablets had a large swelling volume and were mostly loose. Under the influence of mechanical activity, the outer layer could be lost quickly. Figure 4 As shown in the figure, it is the swelling curve of tablets made of different mucosal adhesive materials during the prescription screening process. It can be seen from the figure that compared with xanthan gum (XG), the swelling performance of modified xanthan gum (L-XG) is still maintained at a high level, but lower than xanthan gum, and the swelling performance of modified xanthan gum is higher than other biological mucosal adhesive materials such as chitosan (Chitosan) and sodium carboxymethyl cellulose (HPMC).
[0071] Example 5
[0072] In vitro dissolution study on the drug loading ratio of inner and outer layers of Lactobacillus rhamnosus colonized tablets
[0073] 1. Prepare 20 Lactobacillus rhamnosus oral colonization tablets with an inner and outer layer drug loading ratio of 1:1
[0074] The prescription is as follows:
[0075] Chip:
[0076]
[0077]
[0078] Preparation method: Lactobacillus rhamnosus freeze-dried powder and each auxiliary material are sieved through an 80-mesh sieve, Lactobacillus rhamnosus and auxiliary materials are weighed according to the prescription amount, fully mixed according to the equal amount increment method, sieved and mixed, an appropriate amount of magnesium stearate is added by the external addition method, and after fully mixing, the Lactobacillus rhamnosus tablet core is prepared by the powder direct tableting method. The prescription amount of Lactobacillus rhamnosus freeze-dried powder, L-cysteine xanthan gum, guar gum, and sodium carboxymethyl cellulose are sieved through an 80-mesh sieve, fully mixed according to the equal amount increment method, sieved and mixed, half of the bioadhesive coating material is evenly filled at the bottom of the die, the tablet core is placed in the center, and then the other half of the bioadhesive coating material is filled, and the tablet is directly compressed twice to obtain the tablet.
[0079] 2. Prepare 20 Lactobacillus rhamnosus oral colonization tablets with an inner and outer layer drug loading ratio of 1:0
[0080] Chip:
[0081]
[0082] Outer Layer:
[0083]
[0084] Preparation method: Lactobacillus rhamnosus freeze-dried powder and each auxiliary material are sieved through an 80-mesh sieve, Lactobacillus rhamnosus and auxiliary materials are weighed according to the prescription amount, fully mixed according to the equal amount increment method, sieved and mixed, an appropriate amount of magnesium stearate is added by the external addition method, and after fully mixing, the Lactobacillus rhamnosus tablet core is prepared by the powder direct tableting method. The prescription amount of Lactobacillus rhamnosus freeze-dried powder, L-cysteine xanthan gum, guar gum, and sodium carboxymethyl cellulose are sieved through an 80-mesh sieve, fully mixed according to the equal amount increment method, sieved and mixed, half of the bioadhesive coating material is evenly filled at the bottom of the die, the tablet core is placed in the center, and then the other half of the bioadhesive coating material is filled, and the tablet is directly compressed twice to obtain the tablet.
[0085] 3. Prepare 20 Lactobacillus rhamnosus oral colonization tablets with an inner and outer layer drug loading ratio of 3:1
[0086] Chip:
[0087]
[0088] Outer Layer:
[0089]
[0090] Preparation method: Lactobacillus rhamnosus freeze-dried powder and each auxiliary material are sieved through an 80-mesh sieve, Lactobacillus rhamnosus and auxiliary materials are weighed according to the prescription amount, fully mixed according to the equal amount increment method, sieved and mixed, an appropriate amount of magnesium stearate is added by the external addition method, and after fully mixing, the Lactobacillus rhamnosus tablet core is prepared by the powder direct tableting method. The prescription amount of Lactobacillus rhamnosus freeze-dried powder, L-cysteine xanthan gum, guar gum, and sodium carboxymethyl cellulose are sieved through an 80-mesh sieve, fully mixed according to the equal amount increment method, sieved and mixed, half of the bioadhesive coating material is evenly filled at the bottom of the die, the tablet core is placed in the center, and then the other half of the bioadhesive coating material is filled, and the tablet is directly compressed twice to obtain the tablet.
[0091] 4. Prepare 20 Lactobacillus rhamnosus oral colonization tablets with an inner and outer layer drug loading ratio of 2:1
[0092] Chip:
[0093]
[0094] Outer Layer:
[0095]
[0096]
[0097] Preparation method: Lactobacillus rhamnosus freeze-dried powder and each auxiliary material are sieved through an 80-mesh sieve, Lactobacillus rhamnosus and auxiliary materials are weighed according to the prescription amount, fully mixed according to the equal amount increment method, sieved and mixed, an appropriate amount of magnesium stearate is added by the external addition method, and after fully mixing, the Lactobacillus rhamnosus tablet core is prepared by the powder direct tableting method. The prescription amount of Lactobacillus rhamnosus freeze-dried powder, L-cysteine xanthan gum, guar gum, and sodium carboxymethyl cellulose are sieved through an 80-mesh sieve, fully mixed according to the equal amount increment method, sieved and mixed, half of the bioadhesive coating material is evenly filled at the bottom of the die, the tablet core is placed in the center, and then the other half of the bioadhesive coating material is filled, and the tablet is directly compressed twice to obtain the tablet.
[0098] According to the dissolution test method of the 2020 edition of the Chinese Pharmacopoeia, the dissolution test was conducted on the tablets with a drug loading ratio of 1:0, 3:1, 2:1, and 1:1 for the core and mucosal outer layer, respectively, in 1L of artificial saliva at 37°C using the paddle method. Samples were collected at 0.5h, 1.0h, 1.5h, 2.0h, 3.0h, 4.0h, 6.0h, and 8.0h after the start of the experiment for plate coating. The plates were coated three times in parallel at each time point, and the number of Lactobacillus rhamnosus was counted after culturing at 37°C in an aerobic environment for 48h, and the dissolution curve was drawn. The dissolution results are shown in the figure. Figure 5 As shown, when the inner and outer layer drug loading ratio is 1:0 and 3:1, the dissolution rate of probiotics is low and the six-hour release rate is too low. In the future, further screening and comparison will be carried out on the prescriptions with inner and outer layer drug loading ratios of 2:1 and 1:1.
[0099] In order to simulate the actual dissolution of oral patches in the oral mucosa as much as possible, and to further screen and compare prescriptions with a drug loading ratio of 2:1 and 1:1 between the core and the outer layer of the mucosa, a 50mL EP tube was used as a dissolution test container. The bottom of the container was filled with glass beads of the flow cell method to simulate the oral mucosa. The tablets were adhered to it and 15mL of artificial saliva was added and placed in a shaker at 37°C. The dissolution test was carried out at a speed of 50rpm. Samples were collected at 0.5, 1, 1.5, 2, 3, 4, 5, 6h and when the experiment was completed and completely mixed for plate coating. The plates were coated three times in parallel at each time point, and the number of Lactobacillus rhamnosus was counted and the dissolution curve was drawn after culturing at 37°C in an aerobic environment for 48h. The dissolution results are shown in the figure. Figure 6As shown, the average cumulative release of the prescription with an inner and outer layer drug loading ratio of 2:1 is 65.1% in 6 hours, while the average cumulative release of the prescription with an inner and outer layer drug loading ratio of 1:1 is 78.3% in 6 hours. And through repeated experimental comparisons, it is found that when the drug loading core: outer layer is 1:1, the cumulative drug release rate and amount are better and the curve is smoother, and the drug release is more complete at 4, 5, and 6 hours, reaching 48%, 63%, and 78%, so the prescription with an inner and outer layer drug loading ratio of 1:1 is the optimal prescription.
[0100] The tablets with an internal-external drug loading ratio of 1:1 were fully swollen and scanned using a Japanese Hitachi SU8010 scanning electron microscope. The results are as follows: Figure 7 Scanning electron microscope photos show that after the probiotic oral implant tablets are fully swollen in the simulated oral environment, they have a dense mesh macromolecular structure of gel, which can achieve the effect of sustained release of probiotics. Due to its high viscosity after gelation, it can stay in the local oral environment for a long time, thereby promoting the implantation of probiotics in the oral cavity.
[0101] like Figure 8 As shown, the surface and cross-section of the final prescription tablet were photographed and recorded by a digital camera. From the pictures, it can be observed that the tablet has a round and smooth appearance, and its cross-sectional photo also shows that it has a regular double-layer tablet structure.
Claims
1. A probiotic oral colonization tablet, It is characterized in that It comprises a tablet core and a bioadhesive coating layer, wherein the bioadhesive coating layer is coated on the outside of the tablet core; The probiotic oral colonization tablet is prepared by the following steps: Step 1, mixing a portion of the prescribed amount of probiotic freeze-dried powder, biomineralization material, filler, disintegrant and lubricant, and directly tableting to obtain tablet cores; Step 2, mix the remaining amount of the probiotic lyophilized powder, the biological mucosal adhesive material and the adhesive, take part of the mixture and evenly fill it at the bottom of the tablet press die, place the tablet core at the center, then fill it with the remaining amount of the mixture to wrap it, and directly compress it again to obtain the final tablet; The biomineralization material is casein phosphopeptide-amorphous calcium phosphate, and the biomucosal adhesion material is L-cysteine-modified xanthan gum and guar gum.
2. The probiotic oral implant tablet according to claim 1, It is characterized in that The probiotic freeze-dried powder is Lactobacillus rhamnosus freeze-dried powder, the filler is selected from microcrystalline cellulose and lactose, the disintegrant is cross-linked polyvinyl pyrrolidone, the lubricant is selected from magnesium stearate, sodium stearate and talc, and the binder is sodium carboxymethyl cellulose.
3. The probiotic oral implant tablet according to claim 1, It is characterized in that The probiotic oral implantation tablet is prepared from the following raw materials in percentage by weight: 1% to 5% of Lactobacillus rhamnosus freeze-dried powder, 1% to 5% of casein phosphopeptide-amorphous calcium phosphate, 5% to 10% of microcrystalline cellulose, 20% to 25% of lactose, 0.5% to 1% of cross-linked polyvinyl pyrrolidone, 0.5% to 2% of magnesium stearate, 5% to 15% of L-cysteine-modified xanthan gum, 2% to 5% of guar gum, and 10% to 20% of sodium carboxymethyl cellulose, and the sum of the percentages by weight of all the raw materials is 100%.
4. The probiotic oral colonization tablet according to claim 3, It is characterized in that The weight ratio of the L-cysteine-modified xanthan gum, guar gum and sodium carboxymethyl cellulose is 5:2:8 or 8:5:
8.
5. The probiotic oral implant tablet according to claim 3, It is characterized in that The preparation method of the L-cysteine-modified xanthan gum comprises the following steps: dissolving xanthan gum in water, adjusting the pH value to 5.5, adding EDC and NHS to the solution, adjusting the pH value to 7.0, adding L-cysteine to the mixed solution under light-proof conditions, stirring for reaction, dialyzing with demineralized water after the reaction is completed, and freeze-drying after the dialysis is completed to obtain the L-cysteine-modified xanthan gum.
6. The probiotic oral colonization tablet according to claim 5, It is characterized in that The usage ratio of xanthan gum, EDC and NHS is: every 1.5 g of xanthan gum is dissolved in 200 mL of water, and 0.2875 g of EDC and 0.1726 g of NHS are added thereto; the usage ratio of xanthan gum and L-cysteine is: every 1.5 g of xanthan gum is dissolved in 200 mL of water, and then 1.45 g of L-cysteine is added for reaction.
Citation Information
Patent Citations
Tinidazol colon target biology adhesive tablet and preparation method thereof
CN101422444A
Method for preparing compound double-layer sustained-release medicinal membrane for treating oral mucosal disease
CN101468039A
Oral dosage form
CN106822007A
Nidazole antibacterial drug containing compound medicine for oral administration and preparation method of compound medicine
CN106924289A
Tabletting candy containing mouth cavity probiotics and preparation method of tabletting candy
CN109566825A
